Evidence Grade A — Regulatory approved. 40034 published studies. 606 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Vancomycin is one of medicine's most important antibiotics — the go-to treatment for serious MRSA infections and severe C. difficile gut infections. Available as an intravenous infusion for bloodstream and deep-tissue infections and as an oral formulation for intestinal infections, it has been a cornerstone of hospital medicine since the 1950s and remains on the WHO's List of Essential Medicines.
Vancomycin is also known by these brand and alternate names:
40,034 published studies: 24674 human, 3139 animal, 5288 in-vitro, 4173 reviews
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis.
Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
Vancomycin works by binding to a specific chemical structure (D-Ala-D-Ala) on the building blocks that bacteria use to construct their cell walls. By physically blocking this target with five precise hydrogen bonds, vancomycin prevents the enzymes that cross-link the cell wall from doing their job. Without a properly constructed cell wall, the bacterium cannot maintain its structural integrity and dies. This mechanism targets a fundamental bacterial process that human cells do not use.
With over 60 years of clinical experience, vancomycin is one of the most thoroughly understood antibiotics. It requires regular blood level monitoring to ensure doses are effective without causing kidney damage or hearing loss. Administration must be slow to avoid "Red Man Syndrome" — a flushing reaction caused by rapid infusion. The rise of vancomycin-resistant bacteria (particularly enterococci) is an ongoing concern, and occasional vancomycin-intermediate S. aureus strains have been identified. Despite being nearly 70 years old and despite the availability of newer alternatives like daptomycin and the lipoglycopeptides, vancomycin remains irreplaceable for many serious gram-positive infections. Research continues into optimal dosing strategies, particularly in obese patients and children.
PeptideTrace tracks 606 registered clinical trials for Vancomycin sourced from ClinicalTrials.gov.
Vancomycin and Fecal Microbiota Transplant in a Single Patient With Autism Spectrum Disorder
Expanded Access to Cyclic Irrigation in Patients Undergoing Exchange Arthroplasty
Vancomycin Resistant Enterococci in Patients Awaiting Liver Transplantation at the University of Michigan: Prevalence, Risk Factors, Natural History and Outcome of Colonization
Intraoperative Placement of Vancomycin-impregnated Calcium Sulfate Beads Conjugated With Analgesics to Improve Spine Surgery Outcomes
Intraosseous Antibiotics for Osseointegration
FDA ORIG 1
Health Canada Market Authorisation
FDA SUPPL 14
FDA SUPPL 17
FDA SUPPL 20
FDA SUPPL 21
FDA SUPPL 23
FDA ORIG 1
FDA ORIG 1
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 2
FDA SUPPL 2
FDA SUPPL 3
FDA SUPPL 2
FDA SUPPL 3
FDA SUPPL 4
FDA ORIG 1
FDA ORIG 1
FDA SUPPL 26
FDA SUPPL 27
FDA SUPPL 19
FDA SUPPL 25
FDA SUPPL 17
FDA SUPPL 28
FDA SUPPL 16
FDA SUPPL 20
FDA SUPPL 16
FDA SUPPL 20
FDA SUPPL 23
FDA SUPPL 21
FDA SUPPL 1
FDA SUPPL 14
FDA SUPPL 12
FDA SUPPL 15
FDA SUPPL 27
FDA SUPPL 28
FDA SUPPL 16
FDA SUPPL 9
FDA SUPPL 32
FDA SUPPL 28
FDA ORIG 1
FDA ORIG 1
FDA ORIG 1
FDA ORIG 1
FDA SUPPL 6
FDA SUPPL 4
FDA SUPPL 2
FDA SUPPL 5
FDA SUPPL 1
Vancomycin is a tricyclic glycopeptide from Amycolatopsis orientalis with a 7-amino-acid heptapeptide core, three oxidative cross-links, two sugars, and N-methylation. MW 1,449 Da. Binds D-Ala-D-Ala dipeptide terminus of peptidoglycan precursors through five hydrogen bonds. Activity restricted to gram-positive bacteria. IV 15-20 mg/kg q8-12h for systemic infections; oral 125 mg QID for C. difficile. Half-life 4-6 hours.
Binds D-Ala-D-Ala terminus of lipid II via five hydrogen bonds, creating steric barrier preventing transpeptidase cross-linking. Also inhibits transglycosylation and interferes with C55-PP lipid carrier. Secondary effects include altered membrane permeability and selective RNA synthesis inhibition. Time-dependent killing (optimal 3-5x MIC). Current guidelines recommend AUC24/MIC-guided dosing (target 400-600).
Marketed as Vancocin (approved 1958) and Firvanq (oral, approved January 26, 2018). WHO Essential Medicine. ASAP Trial (N=4,239, NEJM 2023): adding vancomycin to cefazolin for arthroplasty prophylaxis did not reduce SSI. Superior to metronidazole for severe C. difficile (IDSA/SHEA 2021 first-line). Indications: MRSA septicemia, endocarditis, skin/bone/respiratory infections (IV); C. difficile diarrhea, staphylococcal enterocolitis (oral).
Zilucoplan is marketed as Zilbrysq (approved October 2023) for anti-acetylcholine receptor antibody-positive generalised myasthenia gravis in adults. Administered as a daily subcutaneous self-injection. In the RAISE trial, zilucoplan showed statistically significant improvements in both activities of daily living and quantitative muscle strength scores compared to placebo, with improvements evident from week one. Its key differentiator from existing complement inhibitors (eculizumab, ravulizumab) is the self-injectable format — those alternatives require hospital-based intravenous infusions. As with all complement inhibitors, patients require meningococcal vaccination before starting treatment due to increased susceptibility to meningococcal infection.
Bortezomib is marketed as Velcade (approved May 2003) for multiple myeloma and mantle cell lymphoma. Generic versions are available. Originally given intravenously, subcutaneous injection is now preferred as it causes significantly less nerve damage. The VISTA trial established bortezomib-based combination therapy as standard for newly diagnosed myeloma patients ineligible for transplant, with median time to disease progression of 24 months versus 16.6 months with older chemotherapy. Peripheral neuropathy (numbness and tingling in hands and feet) is the main dose-limiting side effect, affecting up to 30% of patients. Bortezomib transformed myeloma from a disease with a median survival of approximately 3 years to one where many patients live a decade or more with sequential treatments.
Daptomycin is marketed as Cubicin (approved September 2003). It is indicated for complicated skin and soft tissue infections and S. aureus bloodstream infections including right-sided endocarditis. Administered as a once-daily intravenous infusion. A key limitation is that daptomycin cannot be used for pneumonia — lung surfactant inactivates the drug. In the bacteraemia trial, daptomycin was non-inferior to vancomycin with significantly lower rates of kidney problems (11% versus 26%). Creatine kinase (CK) levels must be monitored during treatment, as daptomycin can cause muscle toxicity. Generics became available after patent expiry, significantly reducing cost.
Comparisons
Timelines
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
